Grossman Adam S's Form 4 filing
Adma Biologics, Inc.ADMA · filed Dec 9, 2022
- Accession no.
- 0001140361-22-045111
- Filed
- Dec 9, 2022
- Trade date
- Dec 9, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $85.7K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grossman Adam SCIK 0001542517 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2022 | Common Stock | PPurchaseAcquired | +14,983 | $2.86 | +$42,851.38 | 2,203,708 | Direct | |
| Dec 9, 2022 | Common Stock | PPurchaseAcquired | +14,982 | $2.86 | +$42,848.52 | 1,143,426 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.